RELAPSED CANCER

This study is testing a new combination of drugs for adults whose aggressive large B-cell lymphoma has returned or stopped responding to standard treatment. The goal is to see if adding a drug called epcoritamab to a standard chemotherapy regimen (GDP) is safe and effective at sh…

This study is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can help control brain lymphomas that have returned or stopped responding to other treatments. The goal is to see if this approach is safe and can shrink tumors and help people live longer. The…

This study is testing a combination of four drugs—isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how well this combination shrinks the cancer.…

This study is testing whether a new drug called BGB-16673 works better and is safe when combined with other cancer medicines for people with B-cell cancers that have returned or not responded to previous treatments. It will enroll about 80 adults whose cancer has come back or res…

This study aims to develop a safe process for giving the drug teclistamab to patients with advanced multiple myeloma in an outpatient or home setting, rather than requiring a hospital stay. It will enroll 15 patients who have tried at least three other treatments, along with thei…

This study is testing a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) for adults with primary central nervous system lymphoma (PCNSL) that has returned or not responded to prior treatment. The goal is to see if this combination can control the cancer and st…

This study is testing whether adding a new oral drug, roginolisib, to two standard drugs (venetoclax and rituximab) is safe and works better for people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. About 64 participants will receiv…